Immunogen, Inc.

-0.05 (-1.14%)
Products, Regulatory

Immunogen Announces Acceptance Of Biologics License Application For Mirvetuximab Soravtansine

Published: 05/23/2022 11:53 GMT
Immunogen, Inc. (IMGN) - Immunogen Announces Acceptance of Biologics License Application for Mirvetuximab Soravtansine in Ovarian Cancer by US Food and Drug Administration With Priority Review.
Immunogen Inc - PDUFA Date is November 28, 2022.
Immunogen - Continues to Enroll Patients in Confirmatory Mirasol Trial, Expects to Announce Top-line Data From This Study in Early 2023.